Compare MBUU & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MBUU | RCKT |
|---|---|---|
| Founded | 1982 | 1999 |
| Country | United States | United States |
| Employees | N/A | 202 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 560.3M | 534.2M |
| IPO Year | 2013 | N/A |
| Metric | MBUU | RCKT |
|---|---|---|
| Price | $26.05 | $3.47 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 14 |
| Target Price | ★ $32.43 | $29.73 |
| AVG Volume (30 Days) | 309.3K | ★ 4.2M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 127.74 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $807,561,000.00 | N/A |
| Revenue This Year | $1.44 | N/A |
| Revenue Next Year | $10.67 | $51.17 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $24.07 | $2.19 |
| 52 Week High | $39.65 | $8.26 |
| Indicator | MBUU | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 40.27 | 36.23 |
| Support Level | $24.43 | $3.43 |
| Resistance Level | $34.66 | $3.49 |
| Average True Range (ATR) | 0.97 | 0.39 |
| MACD | 0.24 | -0.15 |
| Stochastic Oscillator | 41.30 | 3.69 |
Malibu Boats is a designer and manufacturer of power boats in the United States. It is a market leader in performance sport boats, sold under its Malibu and Axis brands. It acquired Cobalt Boats, a producer of sterndrive boats, in 2017, and Pursuit Boats, which makes high end offshore and outboard motorboats in 2018. In 2021, it purchased Maverick Boat Group, a seller of flat fishing boats, with exposure to bay, dual console, and center console boats. Malibu has also expanded into boat trailers and accessories, and in 2020, began producing its own engines for its performance sport boats.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.